Course Content
GIT & Hepatobiliary-II Module — 4th Year MBBS
AIM CONCEPT INTEGRATION

Nausea and Vomiting: Antiemetic Pharmacology

4th Year MBBS • GIT Module

Connect the vomiting pathways with their dominant receptors, antiemetic drug targets, clinical uses and important cautions for rapid revision. :contentReference[oaicite:0]{index=0}

1. The Topic in One Connected Flow

Vomiting can begin from the gastrointestinal tract, chemoreceptor trigger zone, vestibular system or higher brain centres. Each pathway uses characteristic neurotransmitters. Antiemetic therapy works best when the drug blocks the receptor or mechanism most important in that clinical setting.

Emetic Trigger

Chemotherapy, motion, drugs, delayed gastric emptying or conditioned anxiety
→
Dominant Pathway

GI tract, CTZ, vestibular system or higher centres
→
Key Receptor

5-HT3, D2, H1, M1, NK1 or GABA-related cortical control
→
Drug Target

Ondansetron, metoclopramide, domperidone, H1 blocker, scopolamine, aprepitant or lorazepam
→
Physiological Effect

Reduced emetic signalling; metoclopramide also increases gastric motility
→
Clinical Result

Control of motion sickness, pregnancy-related nausea, gastroparesis or chemotherapy-induced vomiting
→
Important Caution

EPS, QT prolongation, sedation, antimuscarinic effects or prolactin increase

2. Key Clinical Connections

Motion Sickness

Vestibular stimulation → H1 and M1 signalling → nausea and vomiting → H1 antihistamines or scopolamine reduce vestibular input.

Scopolamine → muscarinic blockade → benefit in prevention → dry mouth, blurred vision, urinary retention or confusion may occur.

Gastroparesis and Dopamine Blockade

Metoclopramide → D2 blockade + 5-HT4 stimulation → antiemesis + faster gastric emptying → useful when nausea accompanies delayed gastric emptying.

Central D2 blockade → extrapyramidal effects and prolactin rise; domperidone enters the CNS poorly → fewer motor adverse effects.

Chemotherapy-Induced Vomiting

Acute serotonin release → 5-HT3 activation → ondansetron-class blockade; delayed substance P signalling → NK1 blockade with aprepitant.

Conditioned anxiety before treatment → higher-centre emetic response → benzodiazepine such as lorazepam acts as an adjunct.

3. AIM High-Yield Integration Review

⭐ Chemotherapy → intestinal serotonin release → 5-HT3 activation → ondansetron reduces acute emesis.

⭐ Motion stimulus → vestibular H1/M1 pathways → antihistamines or scopolamine are more logical than a 5-HT3 blocker.
Metoclopramide → D2 blockade + 5-HT4 stimulation → antiemesis plus prokinetic benefit → useful in gastroparesis.
⭐ Central D2 blockade → extrapyramidal effects; this also explains why metoclopramide can oppose levodopa in Parkinson disease.
Domperidone → poor CNS penetration → fewer extrapyramidal effects, but D2 blockade can still increase prolactin and QT prolongation remains important.
Doxylamine + pyridoxine → antihistamine-based control of early pregnancy nausea; promethazine or metoclopramide may also be used in appropriate situations.
Delayed CINV → substance P/NK1 pathway → aprepitant; anticipatory nausea → anxiety/conditioning → lorazepam adjunct.
⭐ Dexamethasone → incompletely defined antiemetic mechanism → strengthens combination therapy in chemotherapy-related and postoperative vomiting.
AIM Exam Trap: Do not choose antiemetics only by the symptom “vomiting.” First identify the dominant pathway: 5-HT3 for acute CINV, NK1 for delayed CINV, H1/M1 for motion sickness, and D2/5-HT4 actions for metoclopramide-related antiemetic and prokinetic effects.
Scroll to Top
💬 WhatsApp Support